CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Qualigen Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Qualigen Therapeutics Inc
1880 Century Park E Ste 1000
Phone: (310) 203-1000p:310 203-1000 LOS ANGELES, CA  90067-1623  United States Ticker: QLGNQLGN

Business Summary
Qualigen Therapeutics, Inc. is a diversified life sciences company. The Company is focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug designation, while also commercializing diagnostics. Its cancer therapeutics pipeline includes QN-302, RAS and QN-247. QN-302 is a small molecule genomic quadruplex (G4) selective transcription inhibitor with a strong binding affinity to G4s prevalent in cancer cells. RAS is a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules for preventing mutated RAS genes’ proteins from binding to their effector proteins; preventing this binding could stop tumor growth, especially in RAS-driven tumors such as pancreatic, colorectal and lung cancers. QN-247 is a deoxyribonucleic acid (DNA) coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer, including triple negative breast cancer, acute myeloid leukemia (AML) and glioblastoma.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/202312/31/2022YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, Chief Executive Officer Michael S.Poirier 67 12/14/2021 5/22/2020
Chief Financial Officer, Vice President - Finance Christopher L.Lotz 58 5/22/2020 5/22/2020
Chief Scientific Officer, Vice President - Research and Development WajdiAbdul-Ahad 70 5/22/2020 5/22/2020
5 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Qualigen, Inc. 2042 Corte Del Nogal Carlsbad CA United States

Business Names
Business Name
NanoSynex Ltd.
QLGN
Qualigen, Inc.
Qualigen, Inc.
RTTR

General Information
Number of Employees: 31 (As of 3/31/2023)
Outstanding Shares: 5,181,058 (As of 11/10/2023)
Shareholders: 627
Stock Exchange: NASD
Federal Tax Id: 201295171
Fax Number: (310) 919-1600
Email Address: info@ritterpharma.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024